We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Subgroup analysis shows treatment efficacy in older patients with relapsed/refractory multiple myeloma, suggesting potential benefits of idecabtagene vicleucel.
No takes yet. Share an insight, caveat, or question.
Ailawadhi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: